Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy
Authors
Keywords
-
Journal
BIODRUGS
Volume 33, Issue 4, Pages 345-352
Publisher
Springer Science and Business Media LLC
Online
2019-07-16
DOI
10.1007/s40259-019-00365-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial
- (2019) Guro L. Goll et al. JOURNAL OF INTERNAL MEDICINE
- Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
- (2019) Julia Bohlius et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Statement: Biosimilars in Oncology
- (2018) Gary H. Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014
- (2018) Ilaria Marcianò et al. Frontiers in Endocrinology
- The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
- (2018) Gianluca Trifirò et al. DRUG SAFETY
- The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
- (2018) Alessandro Armuzzi et al. INFLAMMATORY BOWEL DISEASES
- To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
- (2018) Bente Glintborg et al. ANNALS OF THE RHEUMATIC DISEASES
- The FDA Sentinel Initiative — An Evolving National Resource
- (2018) Richard Platt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PROSIT-BIO Cohort
- (2017) Gionata Fiorino et al. INFLAMMATORY BOWEL DISEASES
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0
- (2017) Shirley V. Wang et al. VALUE IN HEALTH
- Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy
- (2017) Francesco Trotta et al. BMJ Open
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014
- (2016) Ilaria Marcianò et al. BIODRUGS
- Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
- (2016) Balázs Vezér et al. CURRENT MEDICAL RESEARCH AND OPINION
- Designing and incorporating a real world data approach to international drug development and use: what the UK offers
- (2016) Andrew Bate et al. DRUG DISCOVERY TODAY
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
- (2016) Silvio Danese et al. Journal of Crohns & Colitis
- Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study
- (2016) Ylenia Ingrasciotta et al. PLoS One
- How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013
- (2015) Ylenia Ingrasciotta et al. BIODRUGS
- Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
- (2015) Jørgen Jahnsen et al. Expert Review of Gastroenterology & Hepatology
- Biosimilars in rheumatology: the wind of change
- (2013) Christian K Schneider ANNALS OF THE RHEUMATIC DISEASES
- Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
- (2013) Niels S. Vermeer et al. DRUG SAFETY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started